VERX Stock Recent News

VERX LATEST HEADLINES

VERX Stock News Image - globenewswire.com

As 85% of consumers begin summer shopping in late winter, businesses face a new peak season – and a growing need for automated tax technology to manage product complexity and compliance As 85% of consumers begin summer shopping in late winter, businesses face a new peak season – and a growing need for automated tax technology to manage product complexity and compliance

globenewswire.com 2025 Aug 26
VERX Stock News Image - businesswire.com

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in three upcoming investor conferences. Susie Lisa, Senior Vice President, Investor Relations, and Manisha Pai, Executive Director, Investor Relations, will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 11:00 a.m. ET. Reshma Kewalramani, President and Chief Executive Officer, and Duncan McKechnie, Executive Vice P.

businesswire.com 2025 Aug 20
VERX Stock News Image - fool.com

Vertex Pharmaceuticals (VRTX 0.17%) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth opportunities in the process.

fool.com 2025 Aug 20
VERX Stock News Image - seekingalpha.com

This week's Undercovered Dozen spotlights 12 lesser-known stocks and ETFs, offering unique investment opportunities across gold, biotech, income, and tech sectors. B2Gold and Vertex Pharmaceuticals stand out as strong buys, driven by robust fundamentals, sector leadership, and clear growth catalysts for 2025 and beyond. Caution is urged on popular income-focused ETFs like SPYI and ULTY, as structural flaws and capped upside may limit long-term wealth compounding.

seekingalpha.com 2025 Aug 18
VERX Stock News Image - seekingalpha.com

I downgrade Vertex (VERX) to Hold due to macro headwinds and ERP migration delays impacting near-term growth outlook. Cloud momentum and e-invoicing adoption remain strong, but on-premise weakness and slower customer expansion weigh on results. FY25 guidance was cut, and growth reacceleration is now less certain, resetting investor expectations and hurting sentiment.

seekingalpha.com 2025 Aug 15
VERX Stock News Image - seekingalpha.com

A 20% drop in Vertex Pharmaceuticals' stock price since I wrote last month was the impetus to make a re-assessment. But the rating has remained unchanged at Hold. This is despite significantly improved Q2 2025 results, seen in both revenue and non-GAAP earnings' growth, with revenues supported by the likes of Alyftrek and Journavx,. However, an unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led to a price plunge.

seekingalpha.com 2025 Aug 12
VERX Stock News Image - seekingalpha.com

The recent Vertex Pharmaceuticals Incorporated stock drop after VX-993 trial results is overblown; the pain franchise remains robust with multiple promising avenues and ongoing trials. Vertex's CF franchise remains a dominant, reliable growth engine, with new revenue ramps from Casgevy and Journavx set to accelerate diversification. VRTX stock valuation is attractive: forward P/E is favorable versus peers, growth prospects are strong, and insider buying signals management confidence at current prices.

seekingalpha.com 2025 Aug 11
VERX Stock News Image - seekingalpha.com

Vertex, Inc. (NASDAQ:VERX ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David DeStefano - CEO, President & Chairman of the Board John R. Schwab - Chief Financial Officer Joseph J.

seekingalpha.com 2025 Aug 06
VERX Stock News Image - zacks.com

Although the revenue and EPS for Vertex (VERX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com 2025 Aug 06
VERX Stock News Image - zacks.com

Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago.

zacks.com 2025 Aug 06
10 of 50